Pay vs Performance Disclosure, Table


Tabular Pay vs. Performance Disclosures
									Value of Fixed $100 Investment Based On:
Fiscal Period	Summary Compensation Table Total for PEO (1)		Compensation Actually Paid for PEO (2)		Average Summary Compensation Table Total for Non-PEO NEOs (3)		Average Compensation Actually Paid for Non-PEO NEOs (4)		Mirion Technologies Total Shareholder Return (5)		Russell 2000 Index Total Shareholder Return (6)		Net Income (Loss) (7)	Adjusted EBITDA (7)(8)
Fiscal Year 2024	$	5,830,816	$	53,333,639	$	1,302,782	$	4,457,847	$	175	$	203	$(35,500,000)	$203,600,000
Fiscal Year 2023	$	4,883,922	$	18,137,940	$	1,238,261	$	2,020,458	$	103	$	143	$(96,900,000)	$180,700,000
Fiscal Year 2022	$	4,075,099	$	(12,917,132)	$	921,514	$	(55,742)	$	66	$	121	$(288,400,000)	$164,700,000
Partial Fiscal Year 2021	$	6,882,576	$	13,399,948	$	1,114,587	$	1,825,348	$	105	$	140	Successor - $(23,000,000) Predecessor - $(152,400,000)	Successor - $44,500,000 Predecessor - $62,100,000
Fiscal Year 2021	$	20,622,413	$	20,622,413	$	2,684,014	$	2,684,014	$	105	$	137	Predecessor - $(158,400,000)	Predecessor - $152,200,000

Named Executive Officers, Footnote

Mr. Logan was our PEO for all years shown. The amounts reported are the amounts of total compensation reported for our PEO for each corresponding year in the "Total" column of the Summary Compensation Table in each applicable year.

The amounts reported represent the average of the amounts reported for the Company’s NEOs as a group (excluding our PEO), in the “Total” column of the Summary Compensation Table in each applicable year. For Fiscal Year 2021 and Partial Fiscal Year 2021, the Company's non-PEO NEOs were Brian Schopfer and Michael Freed. For Fiscal Year 2022, the Company's non-PEO NEOs were Brian Schopfer, Michael Freed, Loic Eloy and Michael Rossi. For Fiscal Year 2023, the Company's non-PEO NEOs were Brian Schopfer, Loic Eloy and Michael Rossi. For Fiscal Year 2024, the Company's non-PEO NEOs were Brian Schopfer, Loic Eloy, Emmanuelle Lee, and Alison Ulrich.

Peer Group Issuers, Footnote

Represents the weighted peer group TSR. The peer group used for this purpose is the Russell 2000 Industrials Index. The peer group TSR calculated for the Russell 2000 Industrials Index is based on an assumed $100 investment as of 8/20/2020, the first trading day within the July 1, 2020 - June 30, 2021 fiscal period, and the reinvestment of any issued dividends. The Russell 2000 Industrials Index is utilized to help determine executive pay as Company TSR relative to the Russell 2000 Industrials Index is the basis, in part, by which executive performance awards are earned.

PEO Total Compensation Amount

$ 6,882,576

$ 5,830,816

$ 4,883,922

$ 4,075,099

$ 20,622,413

PEO Actually Paid Compensation Amount

13,399,948

$ 53,333,639

18,137,940

(12,917,132)

20,622,413

Adjustment To PEO Compensation, Footnote

The amounts reported represent the “compensation actually paid” to our PEO, computed in accordance with Item 402(v) of Regulation S-K, but do not reflect the actual amount of compensation earned by or paid to our PEO in the applicable year. In accordance with Item 402(v) of Regulation S-K, below are the adjustments made to the amount reported for our PEO in the “Total” column of the Summary Compensation Table for each year to arrive at compensation actually paid to our PEO during each year shown:


PEO "CAP" Calculation Detail
	Fiscal Period
Compensation Element	Fiscal Year 2021		Partial Fiscal Year 2021		Fiscal Year 2022		Fiscal Year 2023		Fiscal Year 2024
Summary Compensation Table (SCT) Reported Total Compensation	$	20,622,413	$	6,882,576	$	4,075,099	$	4,883,922	$	5,830,816
Aggregate SCT Reported Equity Compensation (-)	(19,240,000)		(5,509,532)		(2,901,854)		(3,016,939)		(3,899,987)
(i) Year-End Fair Value of Awards Granted During the FY & Outstanding (+)	19,240,000		5,730,904		2,290,703		4,643,369		6,993,272
(ii) Year-Over-Year Change in Fair Value of Awards Granted During Previous FYs & Outstanding (+/-)	—		6,296,000		(16,021,350)		11,113,865		6,608,003
(iii) Vesting Date Fair Value of Awards Granted & Vested During the Covered FY (+)	—		—		—		—		—
(iv) Year-Over-Year Change in Fair Value of Awards Granted During Previous FYs & Vesting During Covered FY (+/-)	—		—		(359,730)		513,723		37,801,535
(v) Prior FYE Value of Awards Determined to Fail to Meet Vesting Conditions During Covered FY (-)	—		—		—		—		—
(vi) Value of Dividends Paid not Otherwise Reflected in Fair Value Determination or Total Compensation (+)	—		—		—		—		—
"Compensation Actually Paid" Determination	$	20,622,413	$	13,399,948	$	(12,917,132)	$	18,137,940	$	53,333,639

The equity award adjustments for each applicable year include the addition (or subtraction, as applicable) of the following: (i) the year-end fair value of any equity awards granted in the applicable year that are outstanding and unvested as of the end of the year; (ii) the amount of change as of the end of the applicable year (from the end of the prior fiscal year) in fair value of any awards granted in prior years that are outstanding and unvested as of the end of the applicable year; (iii) for awards that are granted and vest in same applicable year, the fair value as of the vesting date; (iv) for awards granted in prior years that vest in the applicable year, the amount equal to the change as of the vesting date (from the end of the prior fiscal year) in fair value; (v) for awards granted in prior years that are determined to fail to meet the applicable vesting conditions during the applicable year, a deduction for the amount equal to the fair value at the end of the prior fiscal year; and (vi) the dollar value of any dividends or other earnings paid on stock or option awards in the applicable year prior to the vesting date that are not otherwise reflected in the fair value of such award or included in any other component of total compensation for the applicable year. The valuation assumptions used to calculate fair values did not materially differ from those disclosed at the time of grant.

Non-PEO NEO Average Total Compensation Amount

1,114,587

$ 1,302,782

1,238,261

921,514

2,684,014

Non-PEO NEO Average Compensation Actually Paid Amount

1,825,348

$ 4,457,847

2,020,458

(55,742)

2,684,014

Adjustment to Non-PEO NEO Compensation Footnote

The amounts reported represent the average “compensation actually paid” to the NEOs other than our PEO as a group, computed in accordance with Item 402(v) of Regulation S-K. The amounts do not reflect the actual average amount of compensation earned by or paid to such NEOs as a group in the applicable year. In accordance with Item 402(v) of Regulation S-K, the following adjustments were made to the average of the amounts reported in the “Total” column of the Summary Compensation Table for the NEOs as a group (excluding our PEO) for each year to determine the compensation actually paid, using the same methodology described above in footnote 2:


Average Non-PEO NEOs "CAP" Calculation Detail
	Fiscal Period
Compensation Element	Fiscal Year 2021		Partial Fiscal Year 2021		Fiscal Year 2022		Fiscal Year 2023		Fiscal Year 2024
Summary Compensation Table (SCT) Reported Total Compensation	$	2,684,014	$	1,114,587	$	921,514	$	1,238,261	$	1,302,782
Aggregate SCT Reported Equity Compensation (-)	(2,104,375)		(550,946)		(454,065)		(505,565)		(524,992)
(i) Year-End Fair Value of Awards Granted During the FY & Outstanding (+)	2,104,375		573,082		362,012		472,866		937,789
(ii) Year-Over-Year Change in Fair Value of Awards Granted During Previous FYs & Outstanding (+/-)	—		688,625		(867,217)		771,458		652,089
(iii) Vesting Date Fair Value of Awards Granted & Vested During the Covered FY (+)	—		—		—		—		—
(iv) Year-Over-Year Change in Fair Value of Awards Granted During Previous FYs & Vesting During Covered FY (+/-)	—		—		(17,986)		43,438		2,090,179
(v) Prior FYE Value of Awards Determined to Fail to Meet Vesting Conditions During Covered FY (-)	—		—		—		—		—
(vi) Value of Dividends Paid not Otherwise Reflected in Fair Value Determination or Total Compensation (+)	—		—		—		—		—
"Compensation Actually Paid" Determination	$	2,684,014	$	1,825,348	$	(55,742)	$	2,020,458	$	4,457,847

The equity award adjustments for each fiscal year include the amounts noted in footnote 2.

Compensation Actually Paid vs. Total Shareholder Return

The Company’s Compensation Committee reviews a variety of Company-wide and individual factors to link executive compensation actually paid with Company and executive performance, not all of which are presented in the Pay versus Performance table above. To promote strong pay-for-performance orientation when setting executive pay levels, the Compensation Committee considers the Company's absolute and relative TSR, short- and long-term business outlook, including net income and Adjusted EBITDA, and the broader market environment. Moreover, the Company calculates compensation to the PEO and other NEOs on a basis different than the amount reported in the Summary Compensation Table and CAP presented in the Pay Versus Performance table, as calculated in accordance with Item 402(v) of Regulation S-K, is not considered by the Board and the Compensation Committee in evaluating or determining executive compensation.

In accordance with Item 402(v) of Regulation S-K, the Company is providing the following descriptions of the relationships between compensation actually paid and the financial performance metrics presented in the Pay versus Performance table. We note, however, that since the five reported periods vary in length, CAP and Company performance may not be immediately comparable on a period-by-period basis. That said, we believe the Pay Versus Performance table shows the alignment between CAP to the NEOs and the Company's performance, consistent with our compensation philosophy as described in our CD&A. Specifically, CAP for the Company's PEO increased from $18,137,940 in Fiscal Year 2023 to $53,333,639 in the most recently completed fiscal period disclosed, and similarly increased for the Company’s average non-PEO NEO from $2,020,457 to $4,457,847 over the same comparable fiscal periods. In line with such increase, and because the Russell 2000 Industrials Index is utilized to help determine executive pay, both the Company TSR and Russell 2000 Industrials Index TSR increased from the last fiscal period disclosed to the most recently completed fiscal period. Further, Adjusted EBITDA, the primary measure used by the Committee to link pay and performance, increased from $180,700,000 in Fiscal Year 2023 to $203,600,000 in the most recently completed fiscal period. Finally, our net loss decreased from $96,900,000 to $35,500,000 in the most recently completed fiscal period.

Compensation Actually Paid vs. Net Income

Compensation Actually Paid vs. Company Selected Measure

Total Shareholder Return Vs Peer Group

Tabular List, Table


Adjusted EBITDA
Adjusted Free Cash Flow
Adjusted Organic Revenue Growth
Relative Total Shareholder Return

Total Shareholder Return Amount

105

$ 175

103

105

Peer Group Total Shareholder Return Amount

$ 140

203

143

121

137

Net Income (Loss)

$ (23,000,000)

$ (152,400,000)

$ (35,500,000)

$ (96,900,000)

$ (288,400,000)

$ (158,400,000)

Company Selected Measure Amount

44,500,000

62,100,000

203,600,000

180,700,000

164,700,000

152,200,000

PEO Name

Mr. Logan

Additional 402(v) Disclosure

TSR for the Company is calculated based on an assumed $100 investment as of 8/20/2020, the first trading day within the July 1, 2020 - June 30, 2021 fiscal period, and the reinvestment of any issued dividends.The dollar amounts reported represent the amount of net income reflected in the Company's audited financial statements for the applicable fiscal year. The amount of net income reported for the fiscal period from July 1, 2020 through December 31, 2021 reflects the net income relating to the Predecessor for July 1, 2021 through October 19, 2021 and the net income relating to the Successor for October 20, 2021 through December 31, 2021.

On October 20, 2021 (the "Closing" or the "Closing Date"), Mirion Technologies (Topco), Ltd. ("Mirion TopCo") consummated its business combination (the "Business Combination") with GS Acquisition Holdings Corp II ("GSAH"). On the Closing Date, GSAH was renamed Mirion Technologies, Inc. As a result of the Business Combination, Mirion's financial statement presentation distinguishes Mirion TopCo as the "Predecessor" for periods prior to the closing of the Business Combination and Mirion Technologies, Inc. as the "Successor" for periods after the Closing. As a result of the application of the acquisition method of accounting for the Successor, the financial statements for the periods following the Closing are presented on a full step-up basis as a result of the Business Combination, and are therefore not comparable to the financial statements of the Predecessor that are not presented on the same full step-up basis due to the Business Combination.

We use financial measures for performance-based compensation purposes, including Adjusted EBITDA and Adjusted Free Cash Flow and Adjusted Organic Revenue, that are not measures of financial performance under GAAP, in particular as compensation targets and for the performance measures described above herein. We believe that non-GAAP financial information, when taken collectively, may be helpful to management and investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. Other companies, including companies in our industry, may calculate similarly titled non-GAAP measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measures as tools for comparison. Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to

their most directly comparable GAAP financial measures and not rely on any single financial measure to evaluate our business.

Measure:: 1

Adjusted EBITDA

The Company Selected Measure is Adjusted EBITDA. While we consider numerous financial and non-financial performance measures for the purpose of evaluating and determining executive compensation, we consider Adjusted EBITDA, which is one of the measures used to determine annual cash incentive compensation and PSU payout for our NEOs, to be the most important performance measure used by to link compensation actually paid to the NEOs for fiscal year 2024 to Company performance. For a reconciliation of Adjusted EBITDA to net income, (loss), please see the reconciliation below under “Tabular List of Performance Measures.” Adjusted EBITDA used for our compensation programs differs from reported adjusted EBITDA due to adjustments to remove impacts of current year acquisitions and setting foreign exchange impacts at the targeted exchange rates.

Adjusted EBITDA is defined as GAAP net income before interest expense, income tax expense, depreciation and amortization adjusted to remove the impact of foreign currency gains and losses, amortization of acquired intangible assets, the impact of purchase accounting on the recognition of deferred revenue, changes in the fair value of warrants, certain non-operating expenses (impairment related to a business held for sale and an equity investment, incremental one-time costs related to the Business Combination, incremental one-time costs associated with becoming a public company, mergers and acquisition expenses, restructuring costs, costs to achieve information technology system integration and efficiency, and costs to achieve integration and operational synergies), stock-based compensation expense, debt extinguishment, goodwill impairment, and the income tax impacts of these adjustments. Adjusted EBITDA used for our compensation programs differs from reported adjusted EBITDA due to adjustments to remove impacts of current year acquisitions and setting foreign exchange impacts at the targeted exchange rates. A reconciliation of Adjusted EBITDA to the most comparable GAAP measure is set forth in the table that follows.


	Successor									Predecessor
(In millions)	Year Ended December 31, 2024			Year Ended December 31, 2023		Year Ended December 31, 2022		From October 20, 2021 through December 31, 2021		From July 1, 2021 through October 19, 2021		Year Ended June 30, 2021
Net loss (GAAP)	$	(36.6)		$	(98.7)	$	(288.4)	$	(23.0)	$	(105.7)	$	(158.4)
Interest expense, net	51.3			57.1		41.9		6.2		52.8		163.2
Income tax provision (benefit)	2.7			(6.6)		(18.2)		(6.8)		(5.6)		(5.9)
Amortization	118.5			131.3		145.8		32.0		19.7		62.8
Depreciation	31.9			31.5		28.7		5.3		6.2		20.8
Stock-based compensation expense	15.6			21.9		31.8		5.3		9.3		—
Increase (decrease) in fair value of warrant liabilities	5.3			24.8		(37.6)		(1.2)		—		—
Goodwill impairment	—			—		211.8		—		—		—
Other impairments	—			—		7.0		—		—		—
Debt extinguishment	—			2.6		—		—		15.9		—
Foreign currency (gain) loss, net	2.2			(0.3)		4.9		1.6		(0.6)		13.4
Revenue reduction from purchase accounting	—			—		—		2.3		4.5		8.0
Cost of revenues impact from inventory valuation purchase accounting	—			—		6.3		15.8		—		5.2
Non-operating expenses	12.7			17.1		30.7		7.0		34.7		43.1
Reported Adjusted EBITDA (Non-GAAP)	203.6			180.7		164.7		$	44.5	$	31.2	$	152.2
Adjustments to remove impacts of current year acquisitions and setting foreign exchange impacts at the targeted exchange rates	2.9			(2.2)		1.8
Adjusted EBITDA for Compensation (Non-GAAP)	$	206.5		$	178.5	$	166.5

Revenues (GAAP)	$	860.8
Adjustments to set foreign exchange impacts at the targeted exchange rates	7.3
Adjusted Revenues for Compensation (Non-GAAP)	$	868.1

Adjusted EBITDA Margin for Compensation (Non-GAAP)	23.788		%

Medical Group


	Successor							Predecessor
(In millions)	Year Ended December 31, 2024			Year Ended December 31, 2023		Year Ended December 31, 2022		Year Ended June 30, 2021
Income from operations (GAAP)	$	22.3		$	13.0	$	(98.9)	$	2.3
Amortization	52.6			54.7		64.3		23.2
Depreciation	20.4			20.5		18.1		10.1
Stock-based compensation expense	1.1			0.7		0.6		—
Goodwill impairment	—			—		87.3		—
Revenue reduction from purchase accounting	—			—		—		8.0
Cost of revenues impact from inventory valuation purchase accounting	—			—		0.9		5.2
Non-operating expenses(1)	8.0			8.6		14.6		3.6
Other income/expense	0.2			—		—		—
Reported Adjusted EBITDA (Non-GAAP)	104.6			97.5		86.9		$	52.4
Adjustments to remove impacts of current year acquisitions and setting foreign exchange impacts at the targeted exchange rates	0.3			(1.1)		(0.3)
Adjusted EBITDA for Compensation (Non-GAAP)	$	104.9		$	96.4	$	86.6

Revenues (GAAP)	$	299.7
Adjustments to set foreign exchange impacts at the targeted exchange rates	0.6
Adjusted Revenues for Compensation (Non-GAAP)	$	300.3

Adjusted EBITDA Margin for Compensation (Non-GAAP)	34.932		%

(1) In FY 2023, non-operating expenses were included in Medical Group and Nuclear & Safety Group segment earnings for the first time. For comparability purposes, reported income (loss) from operations has been adjusted for prior periods. Non-operating expenses only impacted adjusted EBITDA for compensation purposes in FY 2023.

Nuclear & Safety Group


	Successor							Predecessor
(In millions)	Year Ended December 31, 2024			Year Ended December 31, 2023		Year Ended December 31, 2022		Year Ended June 30, 2021
Income from operations (GAAP)	$	78.9		$	46.0	$	(103.1)	$	68.1
Amortization	65.9			76.6		81.5		39.6
Depreciation	10.9			10.3		9.6		10.1
Stock-based compensation expense	1.8			1.3		1.0		—
Goodwill impairment	—			—		124.5		—
Cost of revenues impact from inventory valuation purchase accounting	—			—		5.4		—
Non-operating expenses(1)	2.1			1.1		5.1		13.3
Other income/expense	0.2			0.1		—		0.4
Reported Adjusted EBITDA (Non-GAAP)	159.8			135.4		124.0		$	131.5
Adjustments to remove impacts of current year acquisitions and setting foreign exchange impacts at the targeted exchange rates	2.1			(1.0)		2.0
Adjusted EBITDA for Compensation (Non-GAAP)	$	161.9		$	134.4	$	126.0

Revenues (GAAP)	$	561.1
Adjustments to set foreign exchange impacts at the targeted exchange rates	6.8
Adjusted Revenues for Compensation (Non-GAAP)	$	567.9

Adjusted EBITDA Margin for Compensation (Non-GAAP)	28.509		%

Corporate Group


	Successor						Predecessor
(In millions)	Year Ended December 31, 2024		Year Ended December 31, 2023		Year Ended December 31, 2022		Year Ended June 30, 2021
Income from operations (GAAP)	$	(76.4)	$	(80.9)	$	(95.8)	$	(59.2)
Depreciation	0.6		0.7		1.0		0.6
Stock-based compensation expense	12.7		19.9		30.2		—
Other impairment	—		—		7.0		—
Non-operating expenses(1)	2.2		8.5		11.0		27.0
Other income/expense	0.1		(0.4)		0.4		(0.1)
Reported Adjusted EBITDA (Non-GAAP)	$	(60.8)	$	(52.2)	$	(46.2)	$	(31.7)

Measure:: 2

Adjusted Free Cash Flow

Adjusted Free Cash Flow is defined as free cash flow adjusted to include the impact of cash used to fund certain non-operating expenses described above in the definition of Adjusted EBITDA as well as proceeds from derivative contracts. Free cash flow is defined as GAAP net cash provided by operating activities adjusted to include the impact of purchases of property, plant, and equipment and purchases of badges. Our Adjusted Free Cash Flow used for purposes of our compensation programs are included below, including a reconciliation of Adjusted Free Cash Flow to the most comparable GAAP measure is set forth below:


	Successor						Predecessor
(In millions)	Year Ended December 31, 2024		Year Ended December 31, 2023		Year Ended December 31, 2022		Year Ended June 30, 2021
Net cash provided by operating activities	$	99.1	$	95.2	$	39.4	$	53.6
Purchases of property, plant, and equipment and badges	(48.8)		(37.1)		(34.2)		(23.2)
Free cash flow (non-GAAP)	$	50.3	$	58.1	$	5.2	$	30.4
Proceeds from derivative contracts	4.6		4.4		—		—
Cash used for non-operating expenses	10.5		11.7		30.7		30.8
Other	8.0		(0.6)		—		—
Adjusted free cash flow (non-GAAP)	$	73.4	$	73.6	$	35.9	$	61.2

Measure:: 3

Adjusted Organic Revenue Growth

Adjusted Organic Revenue for our compensation programs is defined as Adjusted Revenue excluding the impact of foreign exchange rates as well as mergers and acquisitions in the period. Adjusted Revenue is defined as GAAP Revenue adjusted to remove the impact of purchase accounting on the recognition of deferred revenue. Adjusted Organic Revenue Growth is calculated by comparing Adjusted Organic Revenue to Adjusted Revenue in the prior year.


	Successor		Successor
(In millions)	Year Ended December 31, 2024		Year Ended December 31, 2023		Year-over-Year Growth Percentage(1)
Revenues (GAAP)	$	860.8	$	800.9
Revenues reduction from purchase accounting	—		—
Adjusted revenues (non-GAAP)	$	860.8	$	800.9
Less effect of acquisitions / divestitures	(7.8)
Less effect of foreign currency translation	0.8
Adjusted organic revenues (non-GAAP)	$	853.8			6.6	%
(1) Year-over-year growth percentage is calculated as 2024 adjusted organic revenues less 2023 adjusted revenues, divided by 2023 adjusted revenues.


	Successor		Successor
(In millions)	Year Ended December 31, 2023		Year Ended December 31, 2022		Year-over-Year Growth Percentage(1)
Revenues (GAAP)	$	800.9	$	717.8
Revenues reduction from purchase accounting	—		—
Adjusted revenues (non-GAAP)	$	800.9	$	717.8
Less effect of acquisitions / divestitures	(10.8)
Less effect of foreign currency translation	(5.7)
Adjusted organic revenues (non-GAAP)	$	784.4			9.3	%
(1) Year-over-year growth percentage is calculated as 2023 adjusted organic revenues less 2022 adjusted revenues, divided by 2022 adjusted revenues.


	Successor		Successor		Predecessor				Combined (Non-GAAP)
(In millions)	Year Ended December 31, 2022		From October 20, 2021 through December 31, 2021		From July 1, 2021 through October 19, 2021		Six Months Ended June 30, 2021		Year Ended December 31, 2021		Year-over-Year Growth Percentage(1)
Revenues (GAAP)	$	717.8	$	154.1	$	168.0	$	346.2	$	668.3
Revenues reduction from purchase accounting	—		2.3		4.5		8.0		14.8
Adjusted revenues (non-GAAP)	$	717.8	$	156.4	$	172.5	$	354.2	$	683.1
Less effect of acquisitions	(27.0)
Less effect of foreign currency translation	31.0
Adjusted organic revenues (non-GAAP)	$	721.8									5.7	%
(1) Year-over-year growth percentage is calculated as 2022 adjusted organic revenues less 2021 combined adjusted revenues, divided by 2021 combined adjusted revenues.

Medical Group


	Successor		Successor
(In millions)	Year Ended December 31, 2024		Year Ended December 31, 2023		Year-over-Year Growth Percentage(1)
Revenues (GAAP)	$	299.7	$	284.5
Revenues reduction from purchase accounting	—		—
Adjusted revenues (non-GAAP)	$	299.7	$	284.5
Less effect of acquisitions / divestitures	(7.8)
Less effect of foreign currency translation	—
Adjusted organic revenues (non-GAAP)	$	291.9			2.6	%
(1) Year-over-year growth percentage is calculated as 2024 adjusted organic revenues less 2023 adjusted revenues, divided by 2023 adjusted revenues.


	Successor		Successor
(In millions)	Year Ended December 31, 2023		Year Ended December 31, 2022		Year-over-Year Growth Percentage(1)
Revenues (GAAP)	$	284.5	$	271.7
Revenues reduction from purchase accounting	—		—
Adjusted revenues (non-GAAP)	$	284.5	$	271.7
Less effect of acquisitions / divestitures	10.1
Less effect of foreign currency translation	(0.8)
Adjusted organic revenues (non-GAAP)	$	293.8			8.1	%
(1) Year-over-year growth percentage is calculated as 2023 adjusted organic revenues less 2022 adjusted revenues, divided by 2022 adjusted revenues.


	Successor		Successor		Predecessor				Combined (Non-GAAP)
(In millions)	Year Ended December 31, 2022		From October 20, 2021 through December 31, 2021		From July 1, 2021 through October 19, 2021		Six Months Ended June 30, 2021		Year Ended December 31, 2021		Year over Year growth Percentage(1)
Revenues (GAAP)	$	271.7	$	49.2	$	60.3	$	103.6	$	213.1
Revenues reduction from purchase accounting	—		2.3		4.5		8.0		14.8
Adjusted revenues (non-GAAP)	$	271.7	$	51.5	$	64.8	$	111.6	$	227.9
Less effect of acquisitions	(11.6)
Less effect of foreign currency translation	2.4
Adjusted organic revenues (non-GAAP)	$	262.5									15.2	%
(1) Year-over-year growth percentage is calculated as 2022 adjusted organic revenues less 2021 combined adjusted revenues, divided by 2021 combined adjusted revenues.

Nuclear & Safety Group


	Successor		Successor
(In millions)	Year Ended December 31, 2024		Year Ended December 31, 2023		Year-over-Year Growth Percentage(1)
Revenues (GAAP)	$	561.1	$	516.4
Revenues reduction from purchase accounting	—		—
Adjusted revenues (non-GAAP)	$	561.1	$	516.4
Less effect of acquisitions / divestitures	—
Less effect of foreign currency translation	0.8
Adjusted organic revenues (non-GAAP)	$	561.9			8.8	%
(1) Year-over-year growth percentage is calculated as 2024 adjusted organic revenues less 2023 adjusted revenues, divided by 2023 adjusted revenues.


	Successor		Successor
(In millions)	Year Ended December 31, 2023		Year Ended December 31, 2022		Year-over-Year Growth Percentage(1)
Revenues (GAAP)	$	516.4	$	446.1
Revenues reduction from purchase accounting	—		—
Adjusted revenues (non-GAAP)	$	516.4	$	446.1
Less effect of acquisitions / divestitures	(20.5)
Less effect of foreign currency translation	(4.9)
Adjusted organic revenues (non-GAAP)	$	491.0			10.1	%
(1) Year-over-year growth percentage is calculated as 2023 adjusted organic revenues less 2022 adjusted revenues, divided by 2022 adjusted revenues.


	Successor		Successor		Predecessor				Combined (Non-GAAP)
(In millions)	Year Ended December 31, 2022		From October 20, 2021 through December 31, 2021		From July 1, 2021 through October 19, 2021		Six Months Ended June 30, 2021		Year Ended December 31, 2021		Year over Year growth Percentage(1)
Revenues (GAAP)	$	446.1	$	104.9	$	107.7	$	242.6	$	455.2
Revenues reduction from purchase accounting	—		—		—		—		—
Adjusted revenues (non-GAAP)	$	446.1	$	104.9	$	107.7	$	242.6	$	455.2
Less effect of acquisitions	(15.4)
Less effect of foreign currency translation	28.6
Adjusted organic revenues (non-GAAP)	$	459.3									0.9	%
(1) Year-over-year growth percentage is calculated as 2022 adjusted organic revenues less 2021 combined adjusted revenues, divided by 2021 combined adjusted revenues.

Measure:: 4

Relative Total Shareholder Return